What is ATYR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ATYR?

P/E (TTM) is n/a and 52-week range is $0.25 to $1.12 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ATYR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ATYR?

The company profile lists revenue (TTM) near $186K, net income (TTM) near $-2.52B, EPS (TTM) near $-0.80 when available from the market-data feed. Figures are informational and may lag live markets.

Where is aTyr Pharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 98M shares outstanding, ISIN US0021202025 when available from company profile and filing metadata.

aTyr Pharma Inc

$ATYR

Health Care · Biotechnology

IR Run Scenarios

$0.25

-3.56%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. The company is headquartered in San Diego, California and currently employs 56 full-time employees. The company went IPO on 2015-05-07. The firm is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).

Employees

Website

www.atyrpharma.com/

IPO

2015-05-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)